GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide, exenatide) are recommended for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, including those with prior MI or ACS, to reduce major MACE beyond glucose lowering [222]. Here, GLP1R is linked to type 2 diabetes mellitus.